Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells. Issue 4 (17th March 2022)

• Record Type: Journal Article
• Authors: Nakano, Dan; Kawaguchi, Takumi; Tsutsumi, Tsubasa; Hayakawa, Masako; Yoshio, Sachiyo; Koga, Hironori; Torimura, Takuji
• Is Part Of: JGH open. Volume 6:Issue 4(2022)
• Page Start: 270
• Page End: 273
• Publication Date: 2022-03-17
• Subjects: chemokine -- cytokine -- hepatoma -- sodium‐glucose cotransporter 2 -- tumor microenvironment
• DOI: 10.1002/jgh3.12730
• Languages: English
• ISSNs: 2397-9070

Abstract

Abstract : (a) Summary for SGLT2i‐induced alterations in 48 chemokines/cytokines in Hep3B and Huh7 cells. (b) SGLT2i‐induced changes in the medium CXCL1 level (each n = 4). (c) SGLT2i‐induced changes in the medium CXCL8 level (each n = 4). (d) SGLT2i‐induced changes in the medium CXCL10 level (each n = 4), (e) SGLT2i‐induced changes in the medium M‐CSF level (each n = 4). The SGLT2i‐induced significant changes in chemokines/cytokines are expressed as the percentage of control (the mean value of the control was set as 100%). CXCL, C‐X‐C motif chemokine ligand; G‐CSF, granulocyte colony‐stimulating factor; IL, interleukin; LIF, leukemia inhibitory factor; M‐CSF, macrophage colony‐stimulating factor; MIP‐1α, macrophage inflammatory protein‐1α; SDF‐1α, stromal‐cell‐derived factor‐1α; TNFα, tumor necrosis factor‐α; VEGF, vascular endothelial growth factor.